Imaging and dosimetric predictors of response and survival in 177 Lu-DOTATATE treatment for neuroendocrine neoplams (EANM 2026) - Sep 29, 2026 - Abstract #OP-258; Pres time: Oct 18, 2026; 04:45 PM - 06:15 PM; Location: Hall G1; "Higher volume-weighted absorbed dose is associated with tumour volume reduction, and in turn, improved disease control and survival. Quantitative SPECT-based volumetric assessment with dosimetry is feasible in routine practice and may inform treatment."
Endocrine Cancer • Neuroendocrine Neoplasm • Solid Tumor
|
|
C. Schmidt 1; S. Spink 2; R. Manavaki 1; C. Abeywickrama Batagodage 2; D. Gillett 2; S. Alsadik 2; D. Inchiappa 3; V. Stokes 3; I. Harper 2; J. Ang 4; R. Casey 3; S. Heard 2; L. Aloj 1
|